Sunday, June 26, 2022

Investing in Harvard Bioscience Inc. (HBIO) Is Getting More Attractive

Harvard Bioscience Inc.’s recent filing unveils that its Chief Executive Officer Green James W acquired Company’s shares for reported $0.11 million on Jun 15. In the deal valued at $3.71 per share,30,000 shares were bought. As a result of this transaction, Green James W now holds 2,301,582 shares worth roughly $ 8.03 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Green James W bought 10,000 shares, generating $34,000 in total proceeds. Upon buying the shares at $3.40, the Chief Executive Officer now owns 2,319,955 shares.

Before that, Green James W bought 30,000 shares. Harvard Bioscience Inc. shares valued at $113,400 were divested by the Chief Executive Officer at a price of $3.78 per share. As a result of the transaction, Green James W now holds 2,309,955 shares, worth roughly $8.06 million.

Meanwhile, The Benchmark Company upgraded its Harvard Bioscience Inc. [HBIO] rating to a Buy from a a Speculative buy in a research note published on Tuesday. A number of analysts have revised their coverage, including Northland Capital’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. KeyBanc Capital Markets began covering HBIO with a “an Overweight” recommendation on November 10, 2020. Janney revised its rating on July 08, 2019. It rated HBIO as “a Neutral” which previously was an “a Buy”.

Price Performance Review of HBIO

On Tuesday, Harvard Bioscience Inc. [NASDAQ:HBIO] saw its stock jump 6.40% to $3.49. On the same session, the stock had its day’s lowest price of $3.38, but rose to a high of $3.50. Over the last five days, the stock has lost -5.68%. Harvard Bioscience Inc. shares have fallen nearly -50.50% since the year began. Nevertheless, the stocks have fallen -52.32% over the past one year. While a 52-week high of $8.75 was reached on 01/04/22, a 52-week low of $3.25 was recorded on 06/17/22. SMA at 50 days reached $4.45, while 200 days put it at $6.11. A total of 0.52 million shares were traded, compared to the trading of 0.33 million shares in the previous session.

Levels Of Support And Resistance For HBIO Stock

The 24-hour chart illustrates a support level at 3.41, which if violated will result in even more drops to 3.34. On the upside, there is a resistance level at 3.53. A further resistance level may holdings at 3.58. The Relative Strength Index (RSI) on the 14-day chart is 39.74, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.57%. Stochastics %K at 8.10% indicates the stock is a buying.

Harvard Bioscience Inc. [HBIO] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 2,797,393 shares, or roughly 6.78% of the outstanding HBIO shares. In other words, the investor’s shares have fallen by -16,078 from its previous 13-F filing of 2813471.0. Additionally, Portolan Capital Management LLC decreased -0.47% of its stake after which the total value it holdings stand at $9,248,048, while Punch & Associates Investment Man added 13.78% of its stake to hold $9.02 million in the firm. Over the last quarter, Harvey Partners LLC purchased 961,000 shares of Harvard Bioscience Inc., while Dimensional Fund Advisors LP bought -5,548 shares. At present, The Vanguard Group, Inc. is holding 1,856,286 shares valued at $6.79 million. Royce & Associates LP owned 1,685,963 shares of the company at the time of its most recent 13F filing, worth $6.17 million.

According to FactSet, Harvard Bioscience Inc.’s share price will average $10.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 204.88 percent from its previous closing price of $3.28. Analysts expect Harvard Bioscience Inc. stock to reach the higher price of $10.00, while the lowest price estimate is $10.00. However, 3 analysts have rated HBIO stock as a Buy in their predictions for 2022. The most recent change occurred on January 24, 2018 when Janney resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $8.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam